The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Exploring Exhaled Breath as a New Platform for Gut Microbiome-Based Diagnostics (HCP Live)
- The Medical Futurist’s 100 Digital Health And AI Companies Of 2026 (The Medical Futurist)
- MedPAC signals need to bolster Medicare physician payments (American Medical Association)
- Want to Reach Nirvana? Try a Colonoscopy. (The New York Times)
- Aidoc Secures FDA Clearance for Healthcare’s First Comprehensive Foundation Model AI (AIdoc)
- NYU Langone Health Announces Gastrointestinal Cancer & Translational Research Leader Dr. Anirban Maitra as New Director of Perlmutter Cancer Center (NYU Langone Health)
- Bringing biomarker testing within reach: CLEAR for CRC to empower patients from day one (Colorectal Cancer Alliance)
- GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test (GRAIL)
